JaLCDOI 10.18926/AMO/58279
フルテキストURL 74_2_179.pdf
著者 Abe, Yoshiyuki| Fujibayashi, Kazutoshi| Nishizaki, Yuji| Yanagisawa, Naotake| Nojiri, Shuko| Kon, Takayuki| Tada, Kurisu| Yamaji, Ken| Tamura, Naoto|
抄録 Glucocorticoids (GCs) have long played a central role in the treatment of systemic lupus erythematosus (SLE), but these drugs have many adverse effects. We will determine whether rapid weekly GC tapering is non-inferior to conventional biweekly tapering in patients with severe SLE. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the relapse-free survival rate at 52 weeks. The main secondary outcome is the prevalence of the Lupus Low Disease Activity State at 52 weeks. The trial will determine the optimal method of tapering GCs in patients with severe SLE.
キーワード systemic lupus erythematosus relapse-free survival rate glucocorticoid, tapering Lupus Low Disease Activity State
Amo Type Clinical Study Protocol
発行日 2020-04
出版物タイトル Acta Medica Okayama
74巻
2号
出版者 Okayama University Medical School
開始ページ 179
終了ページ 183
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 32341595
Web of Science KeyUT 000528278500014
JaLCDOI 10.18926/AMO/56464
フルテキストURL 73_1_85.pdf
著者 Abe, Yoshiyuki| Fujibayashi, Kazutoshi| Nishizaki, Yuji| Yanagisawa, Naotake| Nojiri, Shuko| Nakano, Soichiro| Tada, Kurisu| Yamaji, Ken| Tamura, Naoto|
抄録 Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy.
キーワード pneumocystis pneumonia prophylaxis systemic rheumatic disease sulfamethoxazole-trimethoprim conventional-dose versus half-dose
Amo Type Clinical Study Protocol
発行日 2019-02
出版物タイトル Acta Medica Okayama
73巻
1号
出版者 Okayama University Medical School
開始ページ 85
終了ページ 89
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30820060